Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

Table 3 Impact of on-treatment HBV DNA on 5-year outcomes

	N	VR	P-value	HBeAg loss	P-value	HBeAg seroconversion	P-value
drop of HBV DNA ≥3 log₁₀copies/ml at week 4	12	91.7%	0.06	91.7%	0.013	41.7%	0.083
drop of HBV DNA < 3 log₁₀copies/ml at week 4	35	62.6%		51.4%		17.1%
drop of HBV DNA ≥4 log₁₀copies/ml at week 12	20	85.0%	0.366	80.0%	0.028	45.0%	0.006
drop of HBV DNA < 4 log₁₀copies/ml at week 12	27	60.0%		48.0%		7.4%
DNA level < 4 log₁₀copies/ml at week 24	25	96.0%	< 0.001	84.0%	0.001	36.0%	0.030
DNA level ≥ 4 log₁₀copies/ml at week 24	22	40.9%		36.3%		9.1%
DNA negative at week 52	27	100%	< 0.001	88.9%	< 0.001	33.3%	0.062
DNA positive at week 52	20	45.0%		20.0%		10.0%

ISSN: 1743-422X